Table 1.

Clinical development of novel vaccines for glioblastoma multiforme

Institution/Sponsor	Indication*	Restrictions Phase Status			Source of Information
Dendritic cells with autologous tumor
University of California, Los Angeles	Primary malignant glioma	Resection	II	Recruiting	Clinicaltrials.gov
Northwest Biotherapeutics	Primary GBM	Resection	III	Recruiting	Clinicaltrials.gov
Cedars-Sinai Medical Center, Los Angeles	Primary and recurrent GBM	Resection	II	Completed	Wheeler et al, 2008
Catholic University of Leuven, Belgium	Recurrent GBM	Resection	II	Completed	De Vleeschouwer et al, 2008
Niigata University, Japan	Recurrent malignant gliomas	Resection	I/II	Completed	Yamanaka et al, 2005
Duke University	Recurrent GBM	Resection	I	Recruiting	Clinicaltrials.gov
Dendritic Cells with Peptides
University of Pittsburgh, Pennsylvania	Recurrent GBM	HLA-A2	I/II	Completed	Okada et al, 2011
Children’s Hospital of Pittsburgh	Pediatric primary or recurrent glioma	HLA-A2	I	Recruiting	Clinicaltrials.gov
ImmunoCellular Therapeutics	Primary GBM	HLA-A1 or A2	IIb	Recruiting	Clinicaltrials.gov
Autologous tumor cells
Tokyo Women’s Medical University, Japan	Primary GBM	Resection	I/IIa	Completed	Muragaki et al, 2011
Peptide
Celldex Therapeutics	Primary GBM	EGFRvIII+ tumor	III	Recruiting	Clinicaltrials.gov
Celldex Therapeutics	Recurrent GBM	EGFRvIII + tumor	II	Recruiting	Clinicaltrials.gov
Cancer Research UK/immatics Biotechnologies GmbH	Primary GBM	HLA-A*02	I	Recruiting	Clinicaltrials.gov
GMCI
Advantagene Inc.	Primary malignant glioma	Accessible tumor	II	Active, not recruiting	Clinicaltrials.gov
Dana Farber Cancer Institute, Boston	Pediatric malignant glioma	Accessible tumor	I	Recruiting	Clinicaltrials.gov

GBM glioblastoma multiforme; EGFRvIII endothelial growth factor receptor variant III; HLA-Human leukocyte antigen

^*Primary refers to first diagnosis prior to recurrence